Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global Multicenter, Randomized, Double-blind, Placebo -Controlled, Adaptive Designed Phase Ⅲ Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Ad5-nCoV in Adults 18 Years of Age and Older

NCT04526990 is registered in ClinicalTrials.gov with CanSino Biologics Inc. as lead sponsor.

NCT NCT04526990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04526990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global Multicenter, Randomized, Double-blind, Placebo -Controlled, Adaptive Designed Phase Ⅲ Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Ad5-nCoV in Adults 18 Years of Age and Older
Lead sponsor
CanSino Biologics Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 15, 2020
Completion date
October 21, 2022
Enrollment
44,247 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19